NeuroSense granted patents in Europe, Japan, and Israel for its ALS drug PrimeC

NeuroSense announced that the European, Japan, and Israel Patent Offices have granted the company a key patent relating to “Compositions comprising an anti-inflammatory drug and a dicer activator for use in treatment of neuronal diseases.” The patents relate to NeuroSense’s unique fixed-dose combination of ciprofloxacin and celecoxib, two U.S. FDA approved drugs that are the active ingredients in PrimeC, the company’s lead drug candidate for treating Amyotrophic Lateral Sclerosis. Corresponding patents have been issued in the U.S., Canada, and Australia and are valid through 2038, subject to appropriate maintenance. Additional patent applications relating to the novel formulation of PrimeC and methods for the treatment of other neurodegenerative diseases using NeuroSense’s platform of combination therapies including StabiliC and CogniC are pending as well.